Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1969 1
1970 1
1971 3
1972 1
1973 2
1974 5
1975 1
1977 8
1978 3
1979 6
1980 8
1981 8
1982 4
1983 5
1984 9
1985 9
1986 6
1987 6
1988 7
1989 17
1990 10
1991 10
1992 14
1993 15
1994 15
1995 5
1996 9
1997 9
1998 12
1999 8
2000 15
2001 18
2002 14
2003 19
2004 10
2005 4
2006 8
2007 10
2008 9
2009 11
2010 22
2011 37
2012 30
2013 31
2014 18
2015 10
2016 18
2017 21
2018 15
2019 15
2020 32
2021 29
2022 17
2023 8

Text availability

Article attribute

Article type

Publication date

Search Results

605 results

Results by year

Filters applied: . Clear all
Page 1
Autophagy in metabolic disease and ageing.
Kitada M, Koya D. Kitada M, et al. Nat Rev Endocrinol. 2021 Nov;17(11):647-661. doi: 10.1038/s41574-021-00551-9. Epub 2021 Sep 10. Nat Rev Endocrinol. 2021. PMID: 34508250 Review.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: kitada m. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes.
Kosaka A, Ishibashi K, Nagato T, Kitamura H, Fujiwara Y, Yasuda S, Nagata M, Harabuchi S, Hayashi R, Yajima Y, Ohara K, Kumai T, Aoki N, Komohara Y, Oikawa K, Harabuchi Y, Kitada M, Kobayashi H, Ohkuri T. Kosaka A, et al. Among authors: kitada m. J Exp Med. 2021 Nov 1;218(11):e20200792. doi: 10.1084/jem.20200792. Epub 2021 Sep 24. J Exp Med. 2021. PMID: 34559187 Free PMC article.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Saji S, et al. Among authors: kitada m. Lancet Oncol. 2022 May;23(5):636-649. doi: 10.1016/S1470-2045(22)00196-6. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405087 Clinical Trial.
605 results